Eurofins expands its footprint in Asia with the acquisition of Tsing Hua in Taiwan

Eurofins Scientific (EUFI.PA), a global leader in bioanalytical testing, announces that it has acquired Tsing Hua Testing & Analysis Co., Ltd. (“Tsing Hua”), one of the leading players in environment testing in Taiwan.

Tsing Hua provides a comprehensive suite of testing services for wastewater, drinking water, ground water, fuel gas, ambient air, noise, soil and waste to a broad range of customers in Taiwan. Tsing Hua is headquartered in Hsinchu, with a subsidiary in Taichung and sales offices in four other cities in Taiwan. The company employs around 240 staff.

Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition of Tsing Hua provides Eurofins with a solid entry in the environment testing market in Taiwan. This acquisition will reinforce the Group’s growing footprint in Asia; in return Tsing Hua will gain access to the full range of services and capabilities of the Eurofins Group, which will significantly expand Tsing Hua’s testing portfolio for the benefit of its customers. The acquisitions of Tsing Hua, together with the acquisition of ABM in 2017, another Taiwanese company providing Food Testing services, are a clear demonstration of Eurofins’ commitment to expand its operations in Asia in general and in Taiwan in particular.”

For more information, please visit www.eurofins.com or contact:

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 400 laboratories across 42 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.